» Articles » PMID: 19885117

Treat-to-target Insulin Titration Algorithms when Initiating Long or Intermediate Acting Insulin in Type 2 Diabetes

Overview
Specialty Endocrinology
Date 2009 Nov 4
PMID 19885117
Citations 28
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Until recently, titration of insulin in type 2 diabetes clinical trials was typically left up to the investigator's discretion with a simple statement of the target ranges for glucose. In type 2 diabetes trials the average glycemic control achieved was usually less than desirable. Since then a number of trials have been conducted and reported utilizing various algorithms under various conditions. The objective of this article is to provide a review of the evidence to date.

Methods: In addition to studies already identified through work in the area, the literature was searched using PubMed with the search words "insulin and titration" and subsequently "insulin and algorithm" from which studies starting insulin therapy using insulin titration algorithms in type 2 diabetes were selected.

Results: The different algorithms and achieved results for glycemic control and hypoglycemia, as well as factors appearing to impact the results, are reviewed.

Conclusion: The recent introduction of rigorously implemented insulin titration algorithms when adding on basal insulin to oral drugs in inadequately treated type 2 diabetes patients has led to better average glycemic control with little risk of severe hypoglycemia, as long as the morning fasting plasma glucose target is not lower than 100 mg/dl. Insulin titration algorithms have undergone and continue evolution in the direction of increased patient control.

Citing Articles

Diabetes knowledge, attitudes and practices among Chinese primary care physicians: a cross-sectional study.

Pi L, He B, Fei D, Shi X, Zhou Z BMC Prim Care. 2024; 25(1):348.

PMID: 39342244 PMC: 11438114. DOI: 10.1186/s12875-024-02600-4.


Prospective Study Reveals Host Microbial Determinants of Clinical Response to Fecal Microbiota Transplant Therapy in Type 2 Diabetes Patients.

Ding D, Yong H, You N, Lu W, Yang X, Ye X Front Cell Infect Microbiol. 2022; 12:820367.

PMID: 35402293 PMC: 8990819. DOI: 10.3389/fcimb.2022.820367.


Titration of Long-Acting Insulin Using Continuous Glucose Monitoring and Smart Insulin Pens in Type 1 Diabetes: A Model-Based Carbohydrate-Free Approach.

El Fathi A, Fabris C, Breton M Front Endocrinol (Lausanne). 2022; 12:795895.

PMID: 35082757 PMC: 8785345. DOI: 10.3389/fendo.2021.795895.


Glycaemic profiles of diverse patients with type 2 diabetes using basal insulin: MOBILE study baseline data.

Peters A, Cohen N, Calhoun P, Ruedy K, Beck R, Martens T Diabetes Obes Metab. 2020; 23(2):631-636.

PMID: 33118309 PMC: 7839741. DOI: 10.1111/dom.14238.


A practical approach to the clinical challenges in initiation of basal insulin therapy in people with type 2 diabetes.

Forst T, Choudhary P, Schneider D, Linetzky B, Pozzilli P Diabetes Metab Res Rev. 2020; 37(6):e3418.

PMID: 33098260 PMC: 8519070. DOI: 10.1002/dmrr.3418.


References
1.
Janka H, Plewe G, Riddle M, Kliebe-Frisch C, Schweitzer M, Yki-Jarvinen H . Comparison of basal insulin added to oral agents versus twice-daily premixed insulin as initial insulin therapy for type 2 diabetes. Diabetes Care. 2005; 28(2):254-9. DOI: 10.2337/diacare.28.2.254. View

2.
Gerstein H, Yale J, Harris S, Issa M, Stewart J, Dempsey E . A randomized trial of adding insulin glargine vs. avoidance of insulin in people with Type 2 diabetes on either no oral glucose-lowering agents or submaximal doses of metformin and/or sulphonylureas. The Canadian INSIGHT (Implementing New Strategies.... Diabet Med. 2006; 23(7):736-42. DOI: 10.1111/j.1464-5491.2006.01881.x. View

3.
Hermansen K, Davies M, Derezinski T, Martinez Ravn G, Clauson P, Home P . A 26-week, randomized, parallel, treat-to-target trial comparing insulin detemir with NPH insulin as add-on therapy to oral glucose-lowering drugs in insulin-naive people with type 2 diabetes. Diabetes Care. 2006; 29(6):1269-74. DOI: 10.2337/dc05-1365. View

4.
Yki-Jarvinen H, Kauppinen-Makelin R, Tiikkainen M, Vahatalo M, Virtamo H, Nikkila K . Insulin glargine or NPH combined with metformin in type 2 diabetes: the LANMET study. Diabetologia. 2006; 49(3):442-51. DOI: 10.1007/s00125-005-0132-0. View

5.
Hollander P, Sugimoto D, Vlajnic A, Kilo C . Combination therapy with insulin glargine plus metformin but not insulin glargine plus sulfonylurea provides similar glycemic control to triple oral combination therapy in patients with type 2 diabetes uncontrolled with dual oral agent therapy. J Diabetes Complications. 2015; 29(8):1266-71. DOI: 10.1016/j.jdiacomp.2015.05.022. View